Mycenax Biotech Inc. (TPEX: 4726)
Taiwan
· Delayed Price · Currency is TWD 42.05
+0.05 (0.12%)
Dec 20, 2024, 1:30 PM CST
Mycenax Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 672.85 | 652.62 | 732.28 | 774.27 | 665.34 | 390.84 | Upgrade
|
| Revenue Growth (YoY) | 1.09% | -10.88% | -5.42% | 16.37% | 70.23% | 84.86% | Upgrade
|
| Cost of Revenue | 956.07 | 1,028 | 845.95 | 636.66 | 478.81 | 258.34 | Upgrade
|
| Gross Profit | -283.22 | -375.19 | -113.67 | 137.61 | 186.53 | 132.51 | Upgrade
|
| Selling, General & Admin | 139.88 | 152.23 | 156.16 | 133.96 | 93.77 | 77.14 | Upgrade
|
| Research & Development | 71.31 | 75.81 | 144 | 96.13 | 46.5 | 284.57 | Upgrade
|
| Operating Expenses | 209.8 | 226.91 | 331.32 | 222.94 | 151.13 | 362.76 | Upgrade
|
| Operating Income | -493.03 | -602.1 | -445 | -85.33 | 35.4 | -230.25 | Upgrade
|
| Interest Expense | -24.94 | -23.46 | -15.42 | -1.17 | -0.87 | -1.92 | Upgrade
|
| Interest & Investment Income | 11 | 17.66 | 3.8 | 0.31 | 1.48 | 4.22 | Upgrade
|
| Earnings From Equity Investments | -14.32 | -8.7 | -0.76 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -16.69 | 3.35 | 13.29 | -1.35 | -9.22 | -8.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.84 | -2.06 | 0.21 | -0.11 | 0.9 | 6.58 | Upgrade
|
| EBT Excluding Unusual Items | -530.14 | -615.31 | -443.87 | -87.65 | 27.7 | -229.97 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -20.11 | 0.13 | 0.27 | - | Upgrade
|
| Other Unusual Items | 2.48 | -68.67 | 1.13 | - | - | - | Upgrade
|
| Pretax Income | -527.66 | -683.98 | -462.84 | -87.52 | 27.97 | -229.97 | Upgrade
|
| Income Tax Expense | 8.67 | -1.13 | -9.21 | 2.34 | -2.98 | -11.8 | Upgrade
|
| Net Income | -536.33 | -682.85 | -453.63 | -89.86 | 30.95 | -218.18 | Upgrade
|
| Net Income to Common | -536.33 | -682.85 | -453.63 | -89.86 | 30.95 | -218.18 | Upgrade
|
| Shares Outstanding (Basic) | 206 | 206 | 165 | 148 | 128 | 126 | Upgrade
|
| Shares Outstanding (Diluted) | 206 | 206 | 165 | 148 | 129 | 126 | Upgrade
|
| Shares Change (YoY) | 0.99% | 24.31% | 11.35% | 15.36% | 2.37% | 14.36% | Upgrade
|
| EPS (Basic) | -2.61 | -3.32 | -2.74 | -0.61 | 0.24 | -1.74 | Upgrade
|
| EPS (Diluted) | -2.61 | -3.32 | -2.74 | -0.61 | 0.24 | -1.74 | Upgrade
|
| Free Cash Flow | -546.08 | -426.81 | -777.12 | -1,244 | -86.04 | -318.66 | Upgrade
|
| Free Cash Flow Per Share | -2.65 | -2.08 | -4.70 | -8.38 | -0.67 | -2.53 | Upgrade
|
| Gross Margin | -42.09% | -57.49% | -15.52% | 17.77% | 28.04% | 33.90% | Upgrade
|
| Operating Margin | -73.27% | -92.26% | -60.77% | -11.02% | 5.32% | -58.91% | Upgrade
|
| Profit Margin | -79.71% | -104.63% | -61.95% | -11.61% | 4.65% | -55.82% | Upgrade
|
| Free Cash Flow Margin | -81.16% | -65.40% | -106.12% | -160.71% | -12.93% | -81.53% | Upgrade
|
| EBITDA | -234.17 | -338.27 | -219.7 | 44.33 | 150.83 | -124.95 | Upgrade
|
| EBITDA Margin | -34.80% | -51.83% | -30.00% | 5.72% | 22.67% | -31.97% | Upgrade
|
| D&A For EBITDA | 258.86 | 263.83 | 225.3 | 129.66 | 115.43 | 105.31 | Upgrade
|
| EBIT | -493.03 | -602.1 | -445 | -85.33 | 35.4 | -230.25 | Upgrade
|
| EBIT Margin | -73.27% | -92.26% | -60.77% | -11.02% | 5.32% | -58.91% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.